Literature DB >> 3043009

Response of Kampuchean strains of Plasmodium falciparum to antimalarials: in-vivo assessment of quinine and quinine plus tetracycline; multiple drug resistance in vitro.

M Giboda1, M B Denis.   

Abstract

Forty-three patients were enlisted in the in-vivo test for sensitivity of Kampuchean strains of Plasmodium falciparum to quinine. The mean parasite density count on day 0 was 32,398 asexual parasites per microliter of blood. With a dosage of 1.5 g quinine base daily for 10 days the average parasite clearance time was 5.6 days, and the average duration of fever 3.4 days. The in-vivo test was evaluated at 7 and 10 days after the start of therapy. After 7 days only 16 patients were parasite negative by microscopic examination (S); 20 patients had an RI recrudescence, four patients responded at the RII level and three at the RIII level. Evaluating the in-vivo test at 10 days, the number of patients parasite negative increased to 18, the number of those with an RI level of resistance increased to 21, two patients gave an RII response and two had an RIII level of resistance. Twenty-two adult males were included in an in-vivo test of the sensitivity of P. falciparum to quinine plus tetracycline. The course of treatment was: quinine 3 x 500 mg daily for 10 days, tetracycline 3 x 500 mg for 7 days. Parasite density counts on day 0 averaged 11,393 asexual parasites per microliter of blood. The average parasite clearance time was 5.9 days, and the average duration of fever was 3.8 days. After 7 days of treatment, 81.8% of patients were parasite negative, while one patient had a recrudescence after 17 days (RI). Three infections were resistant at the RII level. By prolongation of the observations to day 10, the parasitaemia was cleared in all patients, i.e. all infections were sensitive to quinine plus tetracycline. Thirty-four patients with falciparum malaria were screened for in-vitro resistance to chloroquine, mefloquine and quinine using the WHO standard micro-test.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3043009

Source DB:  PubMed          Journal:  J Trop Med Hyg        ISSN: 0022-5304


  12 in total

1.  pfcrt polymorphism and chloroquine resistance in Plasmodium falciparum strains isolated in Cambodia.

Authors:  Pharath Lim; Sophy Chy; Frédéric Ariey; Sandra Incardona; Pektra Chim; Rithy Sem; Mey Bouth Denis; Sean Hewitt; Stefan Hoyer; Doung Socheat; Odile Merecreau-Puijalon; Thierry Fandeur
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

2.  Effect of tetracycline on mefloquine pharmacokinetics in Thai males.

Authors:  J Karbwang; K Na Bangchang; D J Back; D Bunnag; W Rooney
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  Differential association of Plasmodium falciparum Na+/H+ exchanger polymorphism and quinine responses in field- and culture-adapted isolates of Plasmodium falciparum.

Authors:  Stéphane Pelleau; Lionel Bertaux; Sébastien Briolant; Michael T Ferdig; Véronique Sinou; Bruno Pradines; Daniel Parzy; Ronan Jambou
Journal:  Antimicrob Agents Chemother       Date:  2011-09-26       Impact factor: 5.191

4.  In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.

Authors:  Hao Meng; Rongping Zhang; Henglin Yang; Qi Fan; Xinzhuan Su; Jun Miao; Liwang Cui; Zhaoqing Yang
Journal:  Antimicrob Agents Chemother       Date:  2010-07-19       Impact factor: 5.191

5.  Quinine treatment selects the pfnhe-1 ms4760-1 polymorphism in Malian patients with Falciparum malaria.

Authors:  Aminatou Kone; Jianbing Mu; Hamma Maiga; Abdoul H Beavogui; Omar Yattara; Issaka Sagara; Mamadou M Tekete; Oumar B Traore; Antoine Dara; Souleymane Dama; Nouhoum Diallo; Aly Kodio; Aliou Traoré; Anders Björkman; Jose P Gil; Ogobara K Doumbo; Thomas E Wellems; Abdoulaye A Djimde
Journal:  J Infect Dis       Date:  2012-11-16       Impact factor: 5.226

6.  In vitro susceptibility of Plasmodium falciparum to monodesethylamodiaquine, quinine, mefloquine and halofantrine in Abidjan (Côte d'Ivoire).

Authors:  W Yavo; K B Bla; A J Djaman; S B Assi; L K Basco; A Mazabraud; M Koné
Journal:  Afr Health Sci       Date:  2010-06       Impact factor: 0.927

7.  Atorvastatin as a potential anti-malarial drug: in vitro synergy in combinational therapy with quinine against Plasmodium falciparum.

Authors:  Véronique Parquet; Maud Henry; Nathalie Wurtz; Jerome Dormoi; Sébastien Briolant; Marine Gil; Eric Baret; Rémy Amalvict; Christophe Rogier; Bruno Pradines
Journal:  Malar J       Date:  2010-05-25       Impact factor: 2.979

8.  Susceptibility of Plasmodium falciparum to different doses of quinine in vivo and to quinine and quinidine in vitro in relation to chloroquine in Liberia.

Authors:  A Björkman; M Willcox; N Marbiah; D Payne
Journal:  Bull World Health Organ       Date:  1991       Impact factor: 9.408

9.  Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine.

Authors:  Maud Henry; Sébastien Briolant; Agnès Zettor; Stéphane Pelleau; Meili Baragatti; Eric Baret; Joel Mosnier; Rémy Amalvict; Thierry Fusai; Christophe Rogier; Bruno Pradines
Journal:  Antimicrob Agents Chemother       Date:  2009-03-09       Impact factor: 5.191

10.  In vitro antimalarial drug susceptibility in Thai border areas from 1998-2003.

Authors:  Wanna Chaijaroenkul; Kesara Na Bangchang; Mathirut Mungthin; Stephen A Ward
Journal:  Malar J       Date:  2005-08-02       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.